<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GEMFIBROZIL</span><br/>(gem-fi'broe-zil)<br/><span class="topboxtradename">Lopid<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antilipemic</span>; <span class="classification">fibrate</span><br/><b>Prototype: </b>Fenofibrate<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>600 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Fibric acid derivative with lipid regulating properties. Blocks lipolysis of stored triglycerides in adipose tissue and inhibits
         hepatic uptake of fatty acids.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Decreases VLDL and therefore triglyceride synthesis. Produces a moderate increase in HDL cholesterol levels and reduces levels
         of total and LDL cholesterol and triglycerides.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Patients with very high serum triglyceride levels (above 750 mg/dL) (type IV and V hyperlipidemia) who have not responded
         favorably to intensive diet restriction and who are at risk of pancreatitis and abdominal pain. Also severe familial hypercholesterolemia
         (type IIa or IIb) that developed in childhood and has failed to respond to dietary control or to other cholesterol-lowering
         drugs.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Gallbladder disease, biliary cirrhosis, hepatic or severe renal dysfunction; pregnancy (category C), lactation. Safety and
         efficacy in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Diabetes mellitus, hypothyroidism; renal impairment, cholelithiasis.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertriglyceridemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 600 mg b.i.d. 30 min before morning and evening meal, may increase up to 1500 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give 30 min before breakfast and evening meal.</li>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, blurred vision. <span class="typehead">GI:</span> <span class="speceff-common">Abdominal</span> or <span class="speceff-common">epigastric pain,</span> diarrhea, nausea, vomiting, flatulence. <span class="typehead">Hematologic:</span> Eosinophilia, mild decreases in Hct, Hgb. <span class="typehead">Musculoskeletal:</span> Painful extremities, back pain, muscle cramps, myalgia, arthralgia, swollen joints. <span class="typehead">Skin:</span> Rash, dermatitis, pruritus, urticaria. <span class="typehead">Endocrine:</span> Hypokalemia, moderate hyperglycemia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May potentiate hypoprothrombinemic effects of <span class="classification">oral anticoagulants</span>; <b>lovastatin</b> increases risk of myopathy and rhabdomyolysis; may increase <b>repaglinide</b> levels and duration of action. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Metabolism:</span> Undergoes enterohepatic circulation. <span class="typehead">Elimination:</span> Excreted primarily in urine; 6% excreted in feces. <span class="typehead">Half-Life:</span> 1.31.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor baseline and at regular intervals during first year of therapy for serum LDL and VLDL, triglycerides, total
            cholesterol, CBC, blood glucose, liver function tests.
         </li>
<li> 							Note: Mild decreases in WBC, Hgb, Hct may occur during early stage of treatment but generally stabilize with continued therapy. 						</li>
<li>Notify physician if the lipid response is not adequate after 3 <i>mo</i> of therapy.
         </li>
<li>Notify physician if patient presents S&amp;S suggestive of cholelithiasis or cholecystitis; gallbladder studies may be indicated.
            Symptoms often occur during the night or early morning; jaundice may or may not be present.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician promptly if unexplained bleeding occurs (e.g., easy bruising, epistaxis, hematuria).</li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li> 							Note: Patients with high serum triglyceride levels are generally advised to lose excess weight and to restrict carbohydrate and
            alcohol intake (alcohol increases serum triglyceride levels). 						
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>